Drug Profile
SAGE 324
Alternative Names: BIIB-124; SAGE-324Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator SAGE Therapeutics
- Class Antiepileptic drugs; Antiparkinsonians; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Essential tremor
- No development reported Epilepsy; Parkinson's disease
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in USA (PO)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (PO)
- 31 Jan 2024 Sage Therapeutics complete enrollment in a phase IIb KINETIC 2 trial in Essential tremor (PO) in USA (NCT05173012)